Mukambro (Ambroxol Hydrochloride)

• Mukambro (ambroxol) is used as a mucolytic to facilitate clearance of airway secretions in several respiratory disorders.
• Acute and chronic bronchitis: reduces mucus viscosity and promotes expectoration, helping patients clear productive coughs.
• Cough with thick or viscous sputum: thins secretions to improve coughing efficiency and relieve discomfort.
• Chronic obstructive pulmonary disease (COPD): assists in maintaining airway patency by decreasing sputum thickness during exacerbations.
• Upper respiratory tract infections: eases congestion by enhancing mucociliary clearance of nasal and bronchial secretions.

• Ambroxol increases the production of pulmonary surfactant and stimulates ciliary activity, which together lower the viscosity of mucus. By enhancing surfactant secretion, it improves the fluidity of bronchial secretions, while ciliary stimulation accelerates mucociliary clearance, allowing easier expectoration of sputum. Additionally, ambroxol exhibits mild anti‑inflammatory activity that may further aid airway patency.

Ambroxol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Taste disturbance or bitter taste in the mouth.
• Nausea or mild stomach discomfort.
• Diarrhea or loose stools.
• Headache or mild dizziness.
• Skin rash or mild itching.

Serious or Rare Side Effects

• Allergic reactions such as swelling of the face, lips, or throat.
• Severe skin reactions including Stevens‑Johnson syndrome.
• Hepatic enzyme elevation or jaundice indicating liver involvement.

• Before using Mukambro, consider the following safety measures.
• Assess renal and hepatic function: adjust use if significant impairment exists.
• Avoid in known hypersensitivity: discontinue if allergic signs appear.
• Use with caution in asthma: monitor for bronchospasm.
• Monitor for gastrointestinal upset: advise patients to report persistent nausea or vomiting.
• Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Ambroxol may interact with other medicines; awareness of potential interactions helps ensure safe use.

Major Interactions (Avoid)

• Concurrent use with strong CYP3A4 inhibitors may increase ambroxol plasma levels (theoretical).
• Combination with other mucolytic agents may heighten risk of gastrointestinal irritation.

Moderate Interactions (Monitor Closely)

• Co‑administration with NSAIDs may increase the likelihood of stomach upset.
• Use together with certain antibiotics may raise the incidence of nausea.
• Concomitant antihistamines may enhance sedation or drowsiness.